Combining two bowel disease medications versus increasing one medication

This trial is testing whether combining two medications—Upadacitinib and Ustekinumab—works better than using a higher dose of Ustekinumab alone for people with Crohn's disease who haven't had enough improvement with standard doses. Researchers want to know if the combination approach helps more people reach remission (a state where the disease is quiet and under control) and whether it's safe to use both medications together.

Some people with Crohn's disease don't respond well enough to standard doses of Ustekinumab alone. Doctors need to know whether adding a second medication or increasing the dose of the current one works better to help these patients feel better and heal their bowel.